TP53BP2

Across TCGA pan-cancer cohorts, TP53BP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TP53BP2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TP53BP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TP53BP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where TP53BP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.619	0.987	<.001	34	view →
LUAD	DFS	Median	All	0.609	0.948	.002	16	view →
PDAC	OS	Tertile	II,III,IV	0.276	0.471	.023	5	view →
LSCC	DFS	Tertile	All	1.000	0.928	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TP53BP2–CCRCC (DFS)

Open the CCRCC breakdown →